| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Soliton has developed breakthrough science for tattoo removal using Rapid Acoustic Pulse (RAP) technology, which when combined with existing laser technology can rapidly accelerate tattoo removal.
Sunovion Pharmaceuticals Inc., known until October 12, 2010 as Sepracor, Inc.
Triton Pharma Inc. is a Concord, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dermesse is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.